Healthcare
Panacea leads $40m Series C for China's XWPharma
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Tencent backs Chinese healthcare cloud services platform
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Chinese mouse-based drug testing specialist raises $143m
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.
Long Hill invests $30m in Chinese O2O pharmacy player
Chinese digital healthcare platform inCarey has raised $30 million in an extended tranche of Series B funding from Long Hill Capital.
Investcorp increases focus on China healthcare
Investcorp has acquired minority stakes in two Chinese healthcare companies – hospital operator Lu Daopei Medical Group and telemedicine platform WeDoctor – paying undisclosed sums.
GL Ventures leads $58m Series B in China’s GemPharmatech
GemPharmatech, a Chinese company that provides genetically-modified mice for use in drug tests, has raised RMB400 million ($58.6 million) Series B led by GL Ventures, the VC arm of Hillhouse Capital.
Bain pursues $374m acquisition of Japan pharmacy business
Bain Capital has agreed to acquire Japanese pharmacy chain store operator Kirindo Holdings through a tender offer that values the business at JPY39.7 billion ($374 million).
DCP invests $283m in Chinese diabetes treatment player
DCP Capital Partners has acquired a 9% stake in Tonghua Dongbao Pharmaceutical, a Chinese pharmaceutical company specializing in diabetes treatment, for RMB1.94 billion ($283.7 million).
China healthcare big data player LinkDoc raises $102m
LinkDoc Technology, a Chinese healthcare big data company, has raised RMB700 million ($102 million) in an extended Series D round from CICC Capital, Youshan Capital, and iFOF, a fund-of-funds launched by CBC Capital and the Tianjin government.
Korean AI drug developer secures $14m Series B
Oncocross, a South Korean drug developer that uses artificial intelligence (AI) to identify new applications for treatments already in clinical trials, has raised KRW16.5 billion ($14 million) in Series B funding led by Smilegate Investment and GNTech...
China biotech player InxMed raises $19m
Ennovation Ventures, a Chinese life sciences and healthcare-focused investor, and China Growth Capital have led a RMB130 million ($19 million) round for local biotech developer InxMed.
Hillhouse leads $418m investment in China's I-Mab
I-Mab Biopharma, a private equity-backed Chinese drug developer that listed in the US as recently as January, has raised $418 million through a private placement.
Vision Fund leads $100m Series C for Singapore-founded Biofourmis
SoftBank Vision Fund has led a $100 million Series C round for Biofourmis, a Singapore founded and now US-based operator of a health analytics platform.
Deal focus: Creador scores as India pharma heats up
Creador's $34 million investment in packaging supplier Shriji Polymers represents an indirect bet on India's growing pharmaceutical industry. Product development and capacity expansion are priorities
Deal focus: Shukun stands out from the crowd
Shukun sought to differentiate itself from other Chinese artificial intelligence medical imaging start-ups by focusing on heart rather than lung conditions, but a COVID-19 diagnosis solution has given the company real traction
Chinese drug developer Adlai Nortye raises $100m Series C
Adlai Nortye, a Chinese biopharma player specializing in cancer treatments, has raised nearly $100 million in Series C round led by Hong Kong-listed contrast research organisation (CRO) Tigermed and Shanghai-based Yingke PE.
Carlyle invests $260m in China's Salubris Pharmaceutical
The Carlyle Group has paid about $260 million for a 5% stake in Shenzhen-listed Salubris Pharmaceutical.
Creador invests $34m in India's Shriji Polymers
Creador has invested INR2.5 billion ($34 million) in Shriji Polymers India, a manufacturer of plastic pharmaceuticals packaging, taking a significant minority stake and providing an exit for Tata Capital.
Qiming joins Series B for Chinese AI diagnosis player
Shukun, a Chinese start-up that develops artificial intelligence (AI) technology used in the medical imaging diagnosis, has raised RMB200 million in the third tranche of Series B round.
BGH, OTPP reengage with New Zealand's Abano
BGH Capital and Ontario Teachers’ Pension Plan (OTPP), which recently terminated an acquisition of New Zealand dentistry chain Abano, have renewed their bid at a lower price.
RA Capital leads round for China's Connect Biopharma
Connect Biopharma, a drug developer based in China and the US, has raised $115 million in Series C funding led by RA Capital Management.
Blackstone agrees $2.3b carve-out from Japan's Takeda
Japan’s Takeda Pharmaceutical has agreed to sell a portfolio of over-the-counter (OTC) medicines and health products to The Blackstone Group for JPY242 billion ($2.3 billion).
Q&A: ChrysCapital Partners' Sanjay Kukreja
Sanjay Kukreja, managing partner at India-focused ChrysCapital Partners, discusses timing, healthcare, technology, and why it makes sense to back entrepreneurs you’ve backed before
China insurance tech platform Waterdrop receives $230m
Shuidi, a China-based insurance technology platform also known as Waterdrop, has raised $230 million in Series D funding jointly led by Tencent Holdings and Swiss Re Group. Existing investors IDG Capital and Wisdom Choice Global Fund re-upped.
